Emotion recollected in tranquility: Lessons learned from the cox-2 saga

Annual Review of Medicine

Volumn 61, Issue , 2010, Pages 17-33

  Grosser, Tilo ^a   Yu, Ying ^a   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular; Cyclooxygenase; Drugs; FDA; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN; PROSTANOID; PROSTANOID RECEPTOR; ROFECOXIB; THROMBOXANE; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ACUTE HEART INFARCTION; ADENOMA; ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; LAW SUIT; LOW DRUG DOSE; PAIN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ULCER HEALING; URINARY EXCRETION; ANIMAL; MOUSE; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT;

ANIMALS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MICE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT;

EID: 77951909982     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-011209-153129     Document Type: Review

References (101)

1. Grosser T, Yusuff S, Cheskis E, et al. 2002. Developmental expression of functional cyclooxygenases in zebrafish. Proc. Natl. Acad. Sci. USA 99:8418-8423
2. Smyth EM, Grosser T, Wang M, et al. 2009. Prostanoids in health and disease. J. Lipid Res. 50(Suppl.):S423-28
3. Grosser T. 2006. The pharmacology of selective inhibition of COX-2. Thromb. Haemost. 96:393-400
4. Stewart WF, Ricci JA, Chee E, et al. 2003. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290:2443-2454
5. Dai C, Stafford RS, Alexander GC. 2005. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch. Intern. Med. 165:171-177
6. FitzGerald GA. 2004. Coxibs and cardiovascular disease. N. Engl. J. Med. 351:1709-1711
7. Vaithianathan R, Hockey PM, Moore TJ, et al. 2009. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf. 32:335-343
8. McAdam BF, Catella-Lawson F, Mardini IA, et al. 1999. Systemic biosynthesis of prostacyclin by cy-clooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96:272-277
9. Catella-LawsonF,McAdamB,Morrison BW, etal. 1999. Effectsofspecific inhibitionofcyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289:735-741
10. Grosser T, Fries S, FitzGerald GA. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116:4-15
11. Brune K, Hinz B. 2004. The discovery and development of antiinflammatory drugs. Arthritis Rheum. 50:2391-2399
12. Marnett LJ, DuBois RN. 2002. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 42:55-80
13. Seibert K, Masferrer J, Zhang Y, et al. 1995. Mediation of inflammation by cyclooxygenase-2. Agents Actions Suppl. 46:41-50
14. FitzGerald GA, Patrono C. 2001. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345:433-442
15. Garavito RM, DeWitt DL. 1999. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim. Biophys. Acta 1441:278-287
16. Picot D, Loll PJ, Garavito RM. 1994. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249
17. O'Banion MK, Winn VD, Young DA. 1992. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89:4888-4892
18. Crofford LJ, Wilder RL, Ristimaki AP, et al. 1994. Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin. Invest. 93:1095-1101
19. Schonbeck U, Sukhova GK, Graber P, et al. 1999. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155:1281-1291
20. McAdam BF, Mardini IA, Habib A, et al. 2000. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest.105:1473-1482
21. Smith WL, Langenbach R. 2001. Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107:1491-1495
22. Ballou LR, Botting RM, Goorha S, et al. 2000. Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl. Acad. Sci. USA 97:10272-10276
23. Yu Y, Cheng Y, Fan J, et al. 2005. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J. Clin. Invest. 115:986-995
24. Vardeh D, Wang D, Costigan M, et al. 2009. COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J. Clin. Invest. 119:287-294
25. Chen M, Boilard E, Nigrovic PA, et al. 2008. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis Rheum. 58:1354-1365
26. Mizuno H, Sakamoto C, Matsuda K, et al. 1997. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397
27. Lipsky PE, Brooks P, Crofford LJ, et al. 2000. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. 160:913-920
28. Schmassmann A, Zoidl G, Peskar BM, et al. 2006. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and-2 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290:G747-56
29. Hatazawa R, Tanaka A, Tanigami M, et al. 2007. Cyclooxygenase-2/ prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G788-97
30. Laine L, Harper S, Simon T, et al. 1999. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776-783
31. Kivitz A, Eisen G, Zhao WW, et al. 2002. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J. Fam. Pract. 51:530-537
32. Bombardier C, Laine L, Reicin A, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343:1520-1528
33. Silverstein FE, Faich G, Goldstein JL, et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
34. Schnitzer TJ, Burmester GR, Mysler E, et al. 2004. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665-674 (Pubitemid 39140622)
35. Laine L, Curtis SP, Cryer B, et al. 2007. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369:465-473
36. Juni P, Rutjes AW, Dieppe PA. 2002. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Br. Med. J. 324:1287-1288 (Pubitemid 34606764)
37. Singh G, Fort JG, Goldstein JL, et al. 2006. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am. J. Med. 119:255-266
38. Yu Y, Fan J, Hui Y, et al. 2007. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J. Biol. Chem. 282:1498-1506
39. So OY, Scarafia LE, Mak AY, et al. 1998. The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J. Biol. Chem. 273:5801-5807
40. Chen W, Pawelek TR, Kulmacz RJ. 1999. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and-2. J. Biol. Chem. 274:20301-20306
41. Yuan C, Rieke CJ, Rimon G, et al. 2006. Partnering between monomers of cyclooxygenase-2 homod-imers. Proc. Natl. Acad. Sci. USA 103:6142-6147
42. Yu Y, Fan J, Chen XS, et al. 2006. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat. Med. 12:699-704
43. Cullen L, Kelly L, Connor SO, et al. 1998. Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 287:578-582
44. Fries S, Grosser T, Price TS, et al. 2006. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130:55-64
45. Schwartz JI, Thach C, Lasseter KC, et al. 2007. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J. Clin. Pharmacol. 47:1521-1531
46. FitzGerald GA, Smith B, Pedersen AK, et al. 1984. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310:1065-1068
47. Roy L, Knapp HR, Robertson RM, et al. 1985. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation 71:434-440
48. Moncada S, Higgs EA, Vane JR. 1977. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1:18-20
49. Topper JN, Cai J, Falb D, et al. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 93:10417-10422
50. FitzGerald GA, Friedman LA, Miyamori I, et al. 1979. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 25:665-672
51. Murata T, Ushikubi F, Matsuoka T, et al. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682
52. Cheng Y, Austin SC, Rocca B, et al. 2002. Role of prostacyclin in the cardiovascular response to throm-boxane A2. Science 296:539-541
53. Cheng Y, Wang M, Yu Y, et al. 2006. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116:1391-1399
54. Cryan LM, Pidgeon GP, Fitzgerald DJ, et al. 2006. COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. Mol. Vis. 12:405-414
55. Cathcart MC, Tamosiuniene R, Chen G, et al. 2008. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J. Pharmacol. Exp. Ther. 326:51-58
56. Seta F, Chung AD, Turner PV, et al. 2009. Renal and cardiovascular characterization of COX-2 knockdown mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R1751-60
57. Yu Y, Ricciotti E, Grosser T, et al. 2009. The translational therapeutics of prostaglandin inhibition in atherothrombosis. J. Thromb. Haemost. 7(Suppl. 1):222-226
58. Mitchell JA, Warner TD. 2006. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug. Discov. 5:75-86
59. Hennan JK, Huang J, Barrett TD, et al. 2001. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104:820-825
60. Pidgeon GP, Tamosiuniene R, Chen G, et al. 2004. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110:2701-2707
61. Buerkle MA, Lehrer S, Sohn HY, et al. 2004. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 110:2053-2059
62. Rabausch K, Bretschneider E, Sarbia M, et al. 2005. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ. Res. 96:e1-6
63. Rudic RD, BrinsterD, Cheng Y, etal. 2005. COX-2-derived prostacyclin modulates vascular remodeling. Circ. Res. 96:1240-1247
64. Kobayashi T, Tahara Y, Matsumoto M, et al. 2004. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114:784-794
65. Egan KM, Lawson JA, Fries S, et al. 2004. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306:1954-1957
66. Wang M, Zukas AM, Hui Y, et al. 2006. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA 103:14507-14512
67. Wang M, Lee E, Song W, et al. 2008. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117:1302-1309
68. Perazella MA, Tray K. 2001. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am. J. Med. 111:64-67
69. Qi Z, Hao CM, Langenbach RI, et al. 2002. Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110:61-69
70. Zewde T, Mattson DL. 2004. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44:424-428
71. Wang D, Patel VV, Ricciotti E, et al. 2009. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc. Natl. Acad. Sci. USA 106:7548-7552
72. Kohsaka S, Volcik KA, Folsom AR, et al. 2008. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196:926-930
73. Arehart E, Stitham J, Asselbergs FW, et al. 2008. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102:986-993
74. Lemaitre RN, Rice K, Marciante K, et al. 2009. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 204:e58-63
75. Kearney PM, Baigent C, Godwin J, et al. 2006. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br. Med. J. 332:1302-1308
76. Kim PS, Reicin AS. 2004. Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351:2875-2878
77. Capone ML, Tacconelli S, Sciulli MG, et al. 2004. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468-1471
78. Psaty BM, Weiss NS. 2007. NSAID trials and the choice of comparators-questions of public health importance. N. Engl. J. Med. 356:328-330
79. Curfman GD, Morrissey S, Drazen JM. 2006. Expression of concern reaffirmed. N. Engl. J. Med. 354:1193
80. Farkouh ME, Kirshner H, Harrington RA, et al. 2004. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364:675-684
81. Ott E, Nussmeier NA, Duke PC, et al. 2003. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125:1481-1492
82. Nussmeier NA, Whelton AA, Brown MT, et al. 2005. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352:1081-1091
83. Furberg CD, Psaty BM, FitzGerald GA. 2005. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111:249
84. Bresalier RS, Sandler RS, Quan H, et al. 2005. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352:1092-1102
85. Baron JA, Sandler RS, Bresalier RS, et al. 2008. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372:1756-1764
86. Baron JA, Sandler RS, Bresalier RS, et al. 2006. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:1674-1682
87. Solomon SD, Pfeffer MA, McMurray JJ, et al. 2006. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028-1035
88. Psaty BM, Potter JD. 2006. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med. 355:950-952
89. Solomon SD, Wittes J, Finn PV, et al. 2008. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104-2113
90. Brownstein JS, SordoM,Kohane IS,etal. 2007. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS One 2:e840
91. Garća Rodriguez LA, Tacconelli S, Patrignani P. 2008. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52:1628-1636
92. Schwartz JI, Dallob AL, Larson PJ, et al. 2008. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J. Clin. Pharmacol. 48:745-754
93. Burleigh ME, Babaev VR, Oates JA, et al. 2002. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105:1816-1823
94. Egan KM, Wang M, Lucitt MB, et al. 2005. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111:334-342
95. Aw TJ, Haas SJ, Liew D, et al. 2005. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med. 165:490-496
96. Cannon CP, Curtis SP, FitzGerald GA, et al. 2006. Cardiovascular outcomes with etoricoxib and di-clofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368:1771-1781
97. Reilly IA, FitzGerald GA. 1987. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180-186
98. Rodŕ?guez LA, Patrignani P. 2006. The ever growing story of cyclo-oxygenase inhibition. Lancet 368. 1745-1747.
99. Tradingmarkets.com. 2008. Pfizer's ills and curesin2008. http://www.tradingmarkets.com/.site/news/TOP%20STORY/2043355/(Accessed Sep. 8, 2009)
100. Couzin J. 2005. Massive trial of celebrex seeks to settle safety concerns. Science 310:1890-1891
101. Solomon DH, Glynn RJ, Rothman KJ, et al. 2008. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 59:1097-1104